This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new poll jointly conducted by Politico and the Harvard Chan School of Public Health bolsters my read on the latter issue – prescriptiondrugpricing, which has become a mass popular culture union. There may be no other issue on voters’ collective minds for the 2018 mid-term election that so unites American voters.
paid for prescriptiondrugs in 2018, with roughly four times the number of health citizens. IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. For context and comparison, note that the U.S.
In 2018, spending on branded prescriptiondrugs will fall in wealthy countries, while spending on specialty drugs will increase, resulting in flat medicines spending. Specifically, $19 billion worth of biotech spending will find biosimilar competition starting in 2018 for the first time. In the U.S.,
This year’s Temkin Experience Index ranked health insurance among the lowest consumer-facing experiences, and Interbrands’ released their 2018 Best Global Brands report this week — which names only a couple of health-focused companies. The Academy convened a team with experience and gravitas to inform this report.
This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescriptiondrugprices. Smart Pharmaceuticals Index (NQSSPH) from May 11, 2018, the date when POTUS and Secretary Azar made their announcement.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content